Podcasts about vineeta agarwala

Rajaie Batniji, MD, PhD, Afia Asamoah, JD, and Sanjay Basu, MD, PhD, cofounders of Waymark, join Vineeta Agarwala, MD, PhD, a16z Bio + Health general partner, to discuss their transformative approach to Medicaid care delivery. This episode dives into their rising risk signal prediction framework, where cutting-edge machine learning predicts patient needs and enables community-based care teams to reduce preventable ER visits and improve health outcomes at scale. The team recently published their real-world results—including a 23% reduction in unnecessary acute care—in the New England Journal of Medicine Catalyst.Additional resources:Supporting Rising-Risk Medicaid Patients Through Early Intervention, NEJM CatalystThe Body Economic: Why Austerity Kills, by David Stuckler and Sanjay Basu

Michael Crackower, PhD, Chief Scientific Officer of Ventus Therapeutics, and Jason Burch, PhD, join Vineeta Agarwala, MD, PhD, general partner at a16z Bio + Health.Together, they talk about how Ventus approaches drug discovery and why they believe we're in the early stages of small molecule innovation. Specifically, we'll hear about the ReSOLVE platform, which enables the drug hunting team to more accurately design and iterate on small molecular compounds for therapeutic applications. They also talk about the current candidates in the pipeline and how they're able to go from idea to IND in record time. 

Lawrence Ingrassia, author and journalist, joins Vineeta Agarwala, general partner, and Kris Tatiossian, editorial lead at a16z Bio + Health. Together, they discuss Larry's recently published book, A Fatal Inheritance: How A Family Misfortune Revealed A Deadly Medical Mystery. In the book, Larry recounts the story of the p53 cancer suppressor gene, also known as the “guardian of the genome.” Mutations in this gene, which can be inherited, remove a natural tumor defense, making it more likely for an individual to get cancer during their lifetime.He tells the story of the search for this gene and the scientists who unlocked the mystery of high familial incidences of cancer, Drs. Li and Fraumeni. He also shares a more personal aspect of the story: many members of his family inherited Li-Fraumeni Syndrome and suffered from multiple cancers themselves.

Brooke Boyarsky Pratt, founder and CEO of knownwell, joins Vineeta Agarwala, general partner at a16z Bio + Health.Together, they talk about the value of obesity medicine practitioners, patient-centric medical homes, and how Brooke believes the metabolic health space will evolve over time.This is the second episode in Raising Health's series on the science and supply of GLP-1s. Listen to last week's episode to hear from Carolyn Jasik, Chief Medical Officer at Omada Health, on GLP-1s from a clinical perspective. Listen to more from Raising Health's series on GLP-1s:The science of satiety: https://raisinghealth.simplecast.com/episodes/the-science-and-supply-of-glp-1s-with-carolyn-jasikHow payors, providers and pricing: https://raisinghealth.simplecast.com/episodes/the-science-and-supply-of-glp-1s-with-chronis-manolis Stay Updated: Let us know what you think: https://ratethispodcast.com/a16zFind a16z on Twitter: https://twitter.com/a16zFind a16z on LinkedIn: https://www.linkedin.com/company/a16zSubscribe on your favorite podcast app: https://a16z.simplecast.com/Follow our host: https://twitter.com/stephsmithioPlease note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.

Brooke Boyarsky Pratt, founder and CEO of knownwell, joins Vineeta Agarwala, general partner at a16z Bio + Health.Together, they talk about the value of obesity medicine practitioners, patient-centric medical homes, and how Brooke believes the metabolic health space will evolve over time.This is the second episode in our series on the science and supply of GLP-1s. Listen to last week's episode to hear from Carolyn Jasik, Chief Medical Officer at Omada Health, on GLP-1s from a clinical perspective.

Vineeta Agarwala, MD, PhD, joins Luke Timmerman's The Long Run podcast on stage at the Life Science Innovation Northwest Conference. They discuss everything from AI for drug discovery to Vineeta's ongoing clinical work as a physician and how that influences her perspective.

Vineeta Agarwala, general partner at A16Z's Bio & Health fund, on investing in AI for drug discovery.

Rosana Kapeller, CEO of Rome Therapeutics, and Marty Taylor, physician-scientist at Harvard Medical School, join Vineeta Agarwala, general partner, and Bryan Faust, investment partner at a16z Bio + Health.Together, they discuss Rosana and Marty's recent publication regarding a virus-like element in our genome known as LINE-1. LINE-1, part of our "dark genome," was ignored as junk DNA for years, but is increasingly recognized to contribute to the pathology of autoimmunity, cancer, neurodegeneration, and aging. Rosana and Marty discuss how the discovery was made as well as how Rome Therapeutics is developing a platform to target LINE-1 and other factors that are part of the "dark genome" for the treatment of disease.Additional reading:Structures, functions and adaptations of the human LINE-1 protein

Jordi Mata-Fink, PhD, cofounder of Gate Bioscience, joins Vineeta Agarwala and Ben Portney of a16z Bio + Health.In this episode, Jordi discusses how he and his cofounders are working to commercialize a novel class of therapeutics, termed 'molecular gates.' His company, Gate, is working to exploit a previously uncharted avenue in cell biology—the secretory translocon—for therapeutic intervention. This approach has the potential to combat diseases otherwise resistant to existing therapeutics.Jordi also imparts valuable insights on the power of platform-based problem-solving and team building.

In this episode, taken from a live a16z event, Bio + Health general partner Vineeta Agarwala moderates a panel of UCSF faculty founders, including Michelle Arkin, Jimmie Ye, and Natalia Jura (full bios below). Together, they discuss fundraising, the decision to stay in or leave  academia after founding a company, and their tips for managing the IP process. Michelle Arkin is a professor of pharmaceutical chemistry at UCSF, chair of the Department of Pharmaceutical Chemistry, and a co-director of the Small Molecule Discovery Center at UCSF. Professor Arkin is also a cofounder of both Elgin Therapeutics and Ambagon Therapeutics.Jimmie Ye is an associate professor of medicine at the Institute for Human Genetics at UCSF and an affiliate investigator at Gladstone Institutes. He is also the cofounder of Dropprint Genomics and Survey Genomics.Natalia Jura is a professor in the Department of Cell and Molecular Pharmacology and an investigator at the Cardiovascular Research Institute at UCSF. Professor Jura is also an associate director of the Quantitative Biosciences Institute. She is a cofounder of Rezo Therapeutics.

This is a crossover episode with The Bioverge Podcast, hosted by Neil Littman. Neil is joined by Vineeta Agarwala, general partner at a16z Bio + Health. Together, they chat about Vineeta's dual role as a clinician and investor, the adoption curve of digital therapeutics, how Vineeta thinks about platforms and a modular, engineering-driven approach to biotech, and much more.

Vineeta Agarwala, General Partner at Andreessen Horowitz's Bio + Health Fund, sits down with Neil to discuss their investment process, how technology is transforming biotech and healthcare, and why she thinks drug development is becoming more and more like software development.

Today marks the reboot of our journal club series, so you can look forward to seeing these episodes as part of our regular feed. This episode is a scientific deep dive on recent research published by Ben Cravatt, Professor in the Department of Chemistry at the Scripps Research Institute and co-founder of a diverse suite of chemoproteomic companies such as Vividion and Belharra Therapeutics, and Gene Yeo, Professor of Cellular and Molecular Medicine at the University of California, San Diego and co-founder of Locana Bio, Eclipse Bio, and Trotana Therapeutics. Ben and Gene are joined by Vineeta Agarwala, general partner at a16z Bio + Health, and bio deal team member Bryan Faust. Together, they'll discuss some unexpected mechanistic results of finding covalent binders to a class of proteins that we are just starting to understand — RNA binding proteins — and the subsequent translational implications that they described in a recent paper published by the Cravatt and Yeo labs in Nature Chemical Biology. The paper outlines a potentially new therapeutic approach that uses small molecules to fundamentally rewire transcriptional networks in cancer cells.Additional reading:Remodeling oncogenic transcriptomes by small molecules targeting NONO

Data can teach us about human health, it's time to invest in it. In this episode, Vineeta Agarwala, physician, investor, and general partner at Andreesen Horowitz, commonly known as a16z, talks about digital health adoption and investing in companies with products that can pragmatically change patient care and increase workforce efficiency. Vineeta speaks about not only being an investor but also a practicing physician and how that impacts her perspective on innovative digital health startups and trends in the healthcare space. Tune in to this episode to learn about the direction the healthcare industry is heading in terms of digital health adoption! Click this link to the show notes, transcript, and resources: outcomesrocket.health

Several years ago, leading VC Marc Andreessen proposed the notion that innovation happens through a process of unbundling and rebundling. Healthcare is no exception. Through the micro-specialization of companies, we've witnessed a great deal of unbundling in the industry. Now, we've begun the process of rebundling. So, what does this mean for the future of healthcare tech? And how do venture investors leverage this idea to decide which digital health startups deserve funding? Dr. Vineeta Agarwala is General Partner at Andreessen Horowitz, where she leads investments for the a16z bio and health fund across digital health care delivery, biotech and life sciences tools and diagnostics. Dr. Agarwala has a special interest in companies leveraging unique datasets to improve healthcare delivery, and she serves on several healthcare portfolio company boards, including Memorial Health, Thyme Care and Waymark. On this episode of HLTH Matters, Dr.  Agarwala joins host Dr. Guatam Gulati to discuss what health payviders are doing to aggregate the best technology for specialty care and how we might integrate such specialized health tech into already complicated workflows. Dr. Agarwala shares her take on the successes and failures of digital health in the last decade, describing how healthcare tech has been transformative for certain patient populations and why she sees most remote connected wearables as a missed opportunity. Listen in to understand how the high bar for fundraising is changing the way a16z makes decisions and get Dr. Agarwala's advice for aspiring founders in healthcare tech. Topics CoveredHow Dr. Agarwala thinks about the unbundling and rebundling of services in healthcareWhat health payviders are doing to aggregate the best possible technology across large numbers of specialty care areasHow we might integrate specialized health tech into already complicated workflows (and why it's such a challenge)Dr. Agarwala's take on patients, providers and payers as joint custodians of healthcare dataThe pros and cons of imposing a government tax on corporations to access healthcare dataHow digital health has been transformative for some small patient populations, health systems and provider practicesWhy Dr. Agarwala sees remote connected wearables as a failure in the absence of intelligent care managementHow the high bar for fundraising has changed the way a16z makes healthcare tech investment decisionsWhy a16z is encouraging its portfolio companies to adopt a lean business modelWhy now is a phenomenal time to start a company in the healthcare technology spaceHow Dr. Agarwala's experience with her grandfather's death informs her work at a16z Connect with Dr. Vineeta AgarwalaDr. Agarwala at Andreessen HorowitzDr. Agarwala on TwitterDr. Agarwala on LinkedIn  Connect with Dr. Guatam GulatiHLTHDr. Gulati on TwitterDr. Gulati on LinkedIn  ResourcesJulie Yoo at Andreesen HorowitzThyme Care

In this episode, we interview Vineeta Agarwala, MD, PhD, a general partner at Andreesen Horowitz (a16z) where she leads investments in the group's bio + health fund. We talk to Vineeta about investing in synthetic biology startup companies, a day in the life of a VC, following the good people, and more!Disclosures:The views expressed here are those of the individual AH Capital Management, L.L.C. (“a16z”) personnel quoted and are not the views of a16z or its affiliates. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, this content may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein.This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. You should consult your own advisers as to those matters. References to any securities or digital assets are for illustrative purposes only, and do not constitute an investment recommendation or offer to provide investment advisory services. Furthermore, this content is not directed at nor intended for use by any investors or prospective investors, and may not under any circumstances be relied upon when making a decision to invest in any fund managed by a16z. (An offering to invest in an a16z fund will be made only by the private placement memorandum, subscription agreement, and other relevant documentation of any such fund and should be read in their entirety.) Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z, and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by Andreessen Horowitz (excluding investments for which the issuer has not provided permission for a16z to disclose publicly as well as unannounced investments in publicly traded digital assets) is available at https://a16z.com/investments/.Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Please see https://a16z.com/disclosures for additional important information.

AI is here...so why isn't it in every clinic? Eric Topol talks with a16z Bio + Health general partners Vijay Pande and Vineeta Agarwala and editorial lead Olivia Webb about what's taking so long, where AI can help patients and providers the most, what needs to happen to speed up adoption, and whether data or policy is more likely to be an obstacle. Eric has written extensively about AI in healthcare, including in his most recent book Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again. He also writes a Substack focused on Covid research, called Ground Truths, linked below.  Finally, as a marker of how AI and AI adoption has (and hasn't) changed over the last few years, check out Eric's 2019 interview with Vijay on the a16z Podcast, also linked below.Ground Truths - https://erictopol.substack.com/a16z Podcast: AI and Your Doctor, Today and Tomorrow - https://a16z.com/2019/06/13/ai-doctor-deep-medicine-topol/ 

In this episode, a16z Bio+Health general partner Vineeta Agarwala spoke with Bobby Franklin, the president and CEO of the National Venture Capital Association, about whether healthcare can be a bipartisan topic, how regulation can potentially enable care models at scale, and the opportunities for collaboration between DC and startups.

Healthcare innovations are improving health outcomes in the United States, and the venture capital industry is leading the way through investment in groundbreaking medical technology. In this episode, we explore what startups need to know about breaking into the healthcare space, navigating government regulations and policies, and developing new systems that do no harm.Vineeta Agarwala, General Partner at Andreessen Horowitz, shares how startups can navigate the challenges in creating better health outcomes, if regulations are a help or a hindrance, and how Washington policymakers can be a better partner in advancing health innovations. Mohamad Makhzoumi, Managing General Partner of Healthcare at New Enterprises Associates, discusses how startups are improving underserved communities access to healthcare, how to create a system that incentivizes disruptive companies to enter the space, and how to deliver lower cost, higher quality healthcare.To register for our events, or to learn more about the National Venture Capital Association (NVCA) visit our website.

On this episode, we discuss three recent papers out in Nature Medicine this week, all examining the deployment of Bayesian Health's AI platform in a clinical setting: Two prospective studies focused on clinician adoption and patient outcomes, and one interview-based study focused on clinical experiences with Bayesian's AI platform, TREWS. First, we get into detail about the design and results of the prospective studies, then we talk about TREWS in context with other clinical decision support tools. Finally, we talk about clinicians' attitudes toward adoption. Featuring Dr. Suchi Saria, PhD, and the CEO of Bayesian Health; Dr. Neri Cohen, MD, PhD, as well as a collaborator with Bayesian Health; and Dr. Vineeta Agarwala, MD, PhD, and a16z general partner. Hosted by Olivia Webb.

Dr. Vineeta Agarwala is a general partner at a16z, physician, adjunct clinical professor at Stanford, previously at Google Ventures, Flatiron Health, having received her MD/PhD at Harvard Medical School and the Broad Institute. Many thanks to Ashlea Kosikowski from 1AB Media for making this episode happen! Follow us on twitter: @TheMaMLPodcast Host: David JH Wu @davidjhwu Producer: Aaron Schumacher @a_schu95 Design: Saurin Kantesaria

Vineeta Agarwala, general partner with Andreesen Horowitz's bio fund, on investing in therapeutics, diagnostics and digital health.

Welcome to 16 Minutes, our show where we talk about tech trends in the news. We have two segments today: 1) The announcement recently that Valve Software, which operates the massive gaming platform Steam, added a rule against games that use blockchain technologies or that allow users to exchange cryptocurrencies or NFTs – this rule appeared on its “What you shouldn't publish on Steam” onboarding list for developers. We go beyond the players to the trends at play here, putting the news in context — as is the premise of this show — because it not only immediately impacts gaming developers and gamers using the platform, but has implications for gaming business models and the arc of innovation in gaming as part of the web3 movement. Our expert guests are a16z partner Jonathan Lai and a16z partner Eddy Lazzarin. 2) The FDA's announcement last month that it authorized marketing of the “first artificial intelligence (AI)-based software designed to identify an area of interest on the prostate biopsy image with the highest likelihood of harboring cancer so it can be reviewed further by the pathologist if the area of concern has not been identified on initial review.” The FDA reviewed the technology from Paige Prostate through its De Novo regulatory pathway. We have three expert guests: Eli Van Allen, associate professor of Medicine at Harvard Medical School and chief of the Division of Population Sciences at the Dana-Farber Cancer Institute; a16z bio general partner Vineeta Agarwala; and a16z bio partner Jay Rughani.

Vineeta Agarwala, MD, PhD, is a General Partner at Andreessen Horowitz (a16z) and adjunct clinical professor in the Division of Primary Care and Population Health at Stanford. She previously worked as a management consultant at McKinsey and as a Director of Product Management at Flatiron Health. At a16z, she works with companies seeking to improve how drug development and patient care delivery is done. We discuss with Dr. Agarwala the importance of adopting a “continuous learner” mindset, how to make the jump from academia to entrepreneurship, and trends in biotech and health tech, including a DoorDash-infrastructure for healthcare delivery. --- Support this podcast: https://anchor.fm/theia-hc/support

In today's episode we have two short segments, both on bioscience topics: [0:00] Moderna has started clinical trials for a flu vaccine, called mRNA-1010, that is based on the same mRNA technology that Moderna and Pfizer used for their COVID vaccines, and that several other companies including Sanofi and Glaxo all are actively working on for the influenza use case. Our experts are general partners Vineeta Agarwala and Jorge Conde of the a16z bio team, who have joined us on many of our vaccine-related episodes, which you can find at a16z.com/vaccines. They discuss what comes next for the clinical trials of this mRNA-based flu vaccines, why companies aren't planning to use the faster and more-targeted mRNA technology for COVID's Delta variant, and how mRNA vaccines will change not only our approach to flu shots but to other respiratory viruses. [9:53] Google's DeepMind AlphaFold, in partnership with the European Molecular Biology Laboratory, is publicly sharing its entire protein structure database -- with predicted protein structure models for ~20,000 proteins expressed by the human genome -- meaning that all its data will be freely and openly available to the scientific community. (We previously discussed DeepMind's AlphaFold protein-folding AI on this show in episode #48.) General partner Vijay Pande of the a16z bio team helps us answer the question: Why does it matter that a huge database of very accurate predicted protein structures is now freely available?

In what ways is digital health for complex care under or overrated? [4:04]Are digital health solutions better suited to tackling clinical or non-clinical needs for complex care? [17:32]The challenge of the physician's inbox [27:55]Have we meaningfully moved the needle on complex digital care? If so, where? [32:08]Should we focus on applying basic tech to easy optimization and automation problems or advanced tech to more complex problems? [41:48] It's Time to Heal, Mondays at 5pm PT on Clubhouse. Join the a16z bio team — Jorge Conde, Vineeta Agarwala, Julie Yoo, and Vijay Pande — plus special guests as they explore all the ways that biology is technology.

Genetic testing is on the cusp of a major revolution, which has the potential to shift not just how we understand our risk for disease, but how we practice healthcare. In the clinic today, genetic testing is used only in cases where we know that mutations have big impact on physiology (BRCA mutations in breast cancer, for example). But our knowledge of how our genetics influences our risk for disease has evolved, and we now know that many (tens of thousands to even millions) small changes in our genes, each of which individually has a tiny effect, combine to influence our risk profile. This new appreciation — coupled with powerful statistical methods and massive datasets — has fueled the creation of a new tool to quantify the risk of a broad range of common diseases: the polygenic risk score. On this episode, which originally aired on January 18, 2021, host Lauren Richardson (@lr_bio) is joined by Peter Donnelly, (@genemodeller Professor of Statistical Science at the University of Oxford and the CEO of Genomics PLC,) and Vineeta Agarwala, (@vintweeta physician-scientist and general partner at a16z), to discuss these scores and how they can reshape healthcare, away from a paradigm of treating illness and towards prevention and maintenance of health. 

Daniel is a physician who wears many hats: inventor, founder, investor, and startup advisor. This week he sat down with another physician, Dr. Vineeta Agarwala, who has taken her clinical expertise to a whole other industry. Vineeta is a General Partner at Andreessen Horowitz, where she leads investments for the storied firm's bio fund (overseeing therapeutics, diagnostics, and digital health).

mRNA research before COVID and how "mRNA is code" [3:21]The early days of COVID: designing a vaccine in 48 hours [5:44]The software behind the vaccine: getting mRNA researchers out of Excel and into a drug design studio [9:11]The first draft of the vaccine was the final draft [11:10]How the government sped up vaccine development for COVID [12:18]What other new vaccines will come from mRNA?  [15:34]How far are we from these mRNA vaccines? What do we need for them to be widely available? [25:31]Open sourcing Moderna  [27:53]When will COVID vaccines be available for a five year old? [29:47]The three factors that matter when dealing with COVID variants [30:46]How might open source shake up biotech [36:41]The moonshot applications for mRNA therapeutics  [39:43]Advice for building a new category in a regulated environment [46:49]The clinical or regulatory advances needed to speed drug time to market [51:08]Challenge trials for vaccines: good or bad idea? [59:11]It's Time to Heal, Mondays at 5pm PT on Clubhouse. Join the a16z bio team — Jorge Conde, Vineeta Agarwala, Julie Yoo, and Vijay Pande — plus special guests as they explore all the ways that biology is technology.

Can the speed and success of COVID-19 trials teach us how to run other trials 5x faster going forward? Can polygenic risk scores be effectively integrated into healthcare systems? Why do 'unique datasets' hold the key to future drug discovery? And why is there a disparity between precision medicine development in cancer and all other disease areas? Dr Vineeta Agarwala, General Partner at the Andreessen Horowitz Bio Fund, answers all these questions and more as she discusses the future of biotech and genomic medicine with Patrick.

Can the speed and success of COVID-19 trials teach us how to run other trials 5x faster going forward? Can polygenic risk scores be effectively integrated into healthcare systems? Why do 'unique datasets' hold the key to future drug discovery? And why is there a disparity between precision medicine development in cancer and all other disease areas? Dr Vineeta Agarwala, General Partner at the Andreessen Horowitz Bio Fund, answers all these questions and more as she discusses the future of biotech and genomic medicine with Patrick.

On the path from scientific discovery to new drug, the clinical trial is a huge — and critical — hurdle. Clinical trials are themselves experiments, and to make sure that they are doing the best possible job at determining the safety and efficacy of the new drug, we need to be able to do experiments on those experiments. But how do you do that in such a highly regulated space? Host Lauren Richardson talks to James Zou, Assistant Professor of Biomedical Data Science at Stanford University, and a16z general partner Vineeta Agarwala, physician and expert on real world data in healthcare, about new research from the Zou lab that uses AI-powered simulations of clinical trials and real world patient data to understand how different designs influence trial outcomes. In particular, looking for designs that can make trials more inclusive, which is key for getting patients access to potentially life-saving care and for running trials efficiently. The conversation covers the inherited rules and assumptions governing which patients can participate in trials, how Dr. Zou, lead author Ruishan Liu, and colleagues combined real world data and computer simulations to challenge these assumptions via a data-driven approach, and how this can inform smarter trial design. The article at the center of today's episode is: "Evaluating eligibility criteria of oncology trials using real-world data and AI" by Ruishan Liu, Shemra Rizzo, Samuel Whipple, Navdeep Pal, Arturo Lopez Pineda, Michael Lu, Brandon Arnieri, Ying Lu, William Capra, Ryan Copping & James Zou, published in Nature.

On this episode of the a16z Bio Clubhouse Show, a16z general partners Vineeta Agarwala, Julie Yoo, Vijay Pande, and Jorge Conde talk to guest Shantanu Nundy, the Chief Medical Officer of Accolade. The conversation covers Dr. Nundy's new book, "Care After Covid: What the Pandemic Revealed Is Broken in Healthcare and How to Reinvent It",  the next steps in the evolution of hospitals, interoperability (or lack thereof), and more.

On this episode of the a16z Bio Clubhouse Show, a16z general partners Vineeta Agarwala, Julie Yoo, and Jorge Conde talk to guests Sean Duffy, cofounder and CEO of Omada Health, Karan Singh, cofounder and COO of Ginger, and Chris Hogg, a serial entrepreneur in the digital health space. The conversation covers go-to-market strategies, financing and aligning incentives, the struggles of interoperability (or lack thereof), and what it is like to build today versus in the early years.

On this episode of the a16z Bio Clubhouse Show, a16z general partners Vineeta Agarwala, Julie Yoo, and Jorge Conde talk to guest Connie Chen, Chief Medical Officer at Lyra health. The conversation covers what makes digital health different from traditional healthcare delivery, how to build a sustainable business model while maintaining high standards for care, and advice for founders of digital health startups.

Today I speak with Vineeta Agarwala, General Partner at Andreessen Horowitz and a physician at Stanford. She shares the importance of capturing time-course, evolving data on patients that range from the molecular to the clinical levels ("deep clinical annotation"), as well as key ingredients of a successful tech-biotech hybrid startup. Check out the glossary of terms, definitions, and resources (and get a sneak peak of the future conversations lined up!) here: bit.ly/datapulse-glossary --- Support this podcast: https://anchor.fm/the-data-pulse/support

While the singularity is nowhere in sight, we're inching closer to a world where more jobs are being replaced or augmented by machines—and industry sentiment ranges from praise to skepticism. In this live session, Professor and Chair of the Department of Medicine at UCSF, Bob Wachter and Google Ventures partner and physician-scientist Vineeta Agarwala voice their views on the divergent paths of AI.